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ORIGINAL ARTICLE
Effect of Lesion Complexity and Clinical Risk 
Factors on the Efficacy and Safety of Dabigatran 
Dual Therapy Versus Warfarin Triple Therapy in 
Atrial Fibrillation After Percutaneous Coronary 
Intervention
A Subgroup Analysis From the REDUAL PCI Trial
Natalia C. Berry, MD; Laura Mauri, MD, MSc; Philippe Gabriel Steg, MD; Deepak L. Bhatt, MD, MPH; Stefan H. Hohnloser, MD; 
Matias Nordaby, MD; Corinna Miede, MSc; Takeshi Kimura, MD, PhD; Gregory Y.H. Lip, MD; Jonas Oldgren, MD;  
Jurriën M. ten Berg, MD, PhD; Christopher P. Cannon, MD; on behalf of the REDUAL PCI Steering Committee and Investigators
BACKGROUND: The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients 
With AF That Undergo a PCI With Stenting) demonstrated that, in patients with atrial fibrillation following percutaneous coronary 
intervention, bleeding risk was lower with dabigatran plus clopidogrel or ticagrelor (dual therapy) than warfarin plus clopidogrel 
or ticagrelor and aspirin (triple therapy). Dual therapy was noninferior for risk of thromboembolic events. Whether these results 
apply equally to patients at higher risk of ischemic events due to lesion complexity or clinical risk factors is unclear.
METHODS: The primary end point was time to first major or clinically relevant nonmajor bleeding event. The composite efficacy 
end point was death, thromboembolic event, or unplanned revascularization. Our prespecified subgroup analysis categorized 
patients by presence of procedural complexity and/or clinical complexity factors at baseline. A modified dual antiplatelet 
therapy score categorized patients according to degree of clinical risk.
RESULTS: Of 2725 patients, 43.1% had clinical complexity factors alone, 9.9% procedural factors alone, 10.0% both, and 
37.0% neither. Risk of the primary bleeding end point was lower in both dabigatran dual therapy groups than warfarin triple 
therapy groups, regardless of procedural and/or clinical lesion complexity (interaction P values: 0.90 and 0.37, respectively). 
Importantly, a similar risk of the efficacy end point was observed between dabigatran dual and warfarin triple therapy, 
regardless of the presence of clinical or procedural complexity factors (interaction P values: 0.67 and 0.54, dabigatran 110 
and 150 mg dual therapy, respectively). Similar benefit was seen for each dose of dabigatran dual therapy for bleeding 
events regardless of dual antiplatelet therapy score (interaction P values: 0.53 and 0.54, respectively), with similar risk of 
thromboembolic events (interaction P values: 0.20 and 0.08, respectively).
CONCLUSIONS: In patients with atrial fibrillation undergoing percutaneous coronary intervention, dabigatran 110 and 150 mg 
dual therapy reduced bleeding risk compared with warfarin triple therapy, with a similar risk of thromboembolic outcomes, 
irrespective of procedural and/or clinical complexity and modified dual antiplatelet therapy score.
REGISTRATION: URL: https://clinicaltrials.gov/; Unique identifier: NCT02164864.
VISUAL OVERVIEW: A visual overview is available for this article.
Key Words: atrial fibrillation ◼ clopidogrel ◼ dabigatran ◼ percutaneous coronary intervention ◼ risk factors ◼ warfarin
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Antiplatelet therapy is indicated following percuta-neous coronary intervention (PCI) to prevent stent thrombosis and cardiovascular events,1 and sys-
temic anticoagulation is required in most patients with 
atrial fibrillation (AF) for prevention of stroke and sys-
temic embolism.2,3 Balancing the requirements for anti-
platelet and antithrombotic therapy against the risk of 
major bleeding associated with this combination treat-
ment can be challenging in patients with AF post-PCI.4–6
The DAPT (dual antiplatelet therapy) trial demonstrated 
that prolonged DAPT (clopidogrel or prasugrel plus aspi-
rin) beyond 12 months after coronary stent placement 
significantly reduced ischemic events but increased bleed-
ing compared with aspirin monotherapy.7 Subsequent sub-
group analysis of the DAPT trial showed that patients with 
complex lesion anatomy had higher rates of stent throm-
bosis and myocardial infarction (MI) than those without 
complex anatomy in the first year independent of treatment 
arm, and a scoring system assessing clinical risk (the DAPT 
score) could predict the ischemic benefit of prolonged 
DAPT.8 This study did not include subjects treated with 
concomitant anticoagulation, and it is unknown whether 
anticoagulation and antiplatelet strategy in subjects with 
AF undergoing PCI should be adjusted according to the 
presence of risk factors for ischemic or bleeding events.
The REDUAL PCI trial (Evaluation of Dual Therapy With 
Dabigatran vs Triple Therapy With Warfarin in Patients With 
AF That Undergo a PCI With Stenting; NCT02164864) 
showed that dual therapy with dabigatran (110 or 150 mg 
twice daily) and clopidogrel or ticagrelor reduced the risk 
of the primary end point of International Society on Throm-
bosis and Haemostasis-defined major bleeding events 
(MBEs) or clinically relevant nonmajor bleeding events 
versus triple therapy consisting of warfarin, aspirin, and 
clopidogrel or ticagrelor in patients with AF who underwent 
PCI.9,10 Dabigatran dual therapy was noninferior to warfa-
rin triple therapy for the risk of thromboembolic events.9 
This prespecified subgroup analysis assessed the effects 
of procedural or clinical complexity and clinical risk factors, 
as well as DAPT score category, on safety and efficacy 
outcomes in the REDUAL PCI trial.
METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Study Design and Patients
REDUAL PCI was a multicenter, prospective, randomized, open-
label, blinded-end point, active-comparator study in which 2725 
patients with AF who underwent PCI were randomized to 1 of 
2 doses of dabigatran dual therapy (110 or 150 mg twice daily) 
or warfarin triple therapy. Elderly patients (aged ≥80 years out-
side the United States [≥70 years in Japan]) were randomized to 
warfarin triple therapy or dabigatran 110 mg dual therapy only.9,10
The REDUAL PCI trial included patients aged ≥18 years 
with nonvalvular AF following successful PCI within the previ-
ous 120 hours. The indication for PCI was acute coronary syn-
drome (ACS) or stable coronary artery disease. Key exclusion 
criteria included the presence of bioprosthetic or mechanical 
heart valves, severe renal insufficiency (ie, creatinine clear-
ance <30 mL/minute), or other major coexisting conditions. 
International Review Board approval was obtained at all sites, 
and all patients provided written informed consent.
Study Assessments
The primary safety end point of REDUAL PCI was time to 
first International Society on Thrombosis and Haemostasis-
defined MBE or clinically relevant nonmajor bleeding event 
in a time-to-event analysis over a mean follow-up of 14 
months.9,10 A key secondary end point was a composite of 
death or thromboembolic event (DTE; MI, stroke, or systemic 
embolism) or unplanned revascularization (PCI or coronary 
artery bypass grafting).9,10
Complexity Factors
Procedural and clinical complexity factors in the current analysis 
are based on prespecified risk factors employed in the DAPT trial.11 
Nonstandard Abbreviations and Acronyms
ACS acute coronary syndrome
AF atrial fibrillation
DAPT dual antiplatelet therapy
DTE death or thromboembolic event
MI myocardial infarction
PCI percutaneous coronary intervention
WHAT IS KNOWN
• The REDUAL PCI trial (Evaluation of Dual Therapy 
With Dabigatran vs Triple Therapy With Warfarin in 
Patients With AF That Undergo a PCI With Stent-
ing) showed that dual therapy with dabigatran (110 
or 150 mg twice daily) and clopidogrel or ticagrelor 
reduced the risk of bleeding events compared with 
triple therapy consisting of warfarin, aspirin, and 
clopidogrel or ticagrelor in patients with atrial fibril-
lation who underwent percutaneous coronary inter-
vention, with similar thromboembolic outcomes.
WHAT THE STUDY ADDS
• This subgroup analysis of the REDUAL PCI trial 
categorized patients into clinical complexity risk 
factors alone, procedural risk factors alone, both, 
or neither.
• We observed that dabigatran dual therapy consis-
tently reduced bleeding risk compared with warfarin 
triple therapy in patients with and without proce-
dural and/or clinical risk factors for adverse events 
and showed similar thromboembolic outcomes.
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Procedural complexity factors included the following: >2 vessels 
stented, in-stent restenosis of a drug-eluting stent, prior brachy-
therapy, unprotected left main stented, >2 lesions per vessel, lesion 
length ≥30 mm, bifurcation lesion with a side branch ≥2.5 mm, vein 
bypass graft, and a thrombus-containing lesion. Clinical complexity 
factors comprised the following: ACS, acute ST-elevation MI, renal 
insufficiency/failure, and left ventricular ejection fraction <30%.11
Complexity factors were analyzed in 4 subgroups in the 
REDUAL PCI trial: group 1, no procedural or clinical complexity 
factors; group 2, procedural complexity factors alone; group 3, 
clinical complexity factors alone; and group 4, both procedural 
and clinical complexity factors.
Modified DAPT Score Assessments
The DAPT score is a clinical risk score to predict the differ-
ence between the anticipated benefit (ie, reduction in ischemic 
events) versus harm (increased bleeding events) associated 
with DAPT following PCI.12 The original DAPT score ranged 
from −2 to 10, assigning points as follows: 0, age <65 years; 
−1, 65 to <75 years, and −2, ≥75 years; 2, vein graft PCI; 1, 
cigarette smoking, current or within past year; 1, diabetes mel-
litus; 1, MI at presentation; 1, stent diameter <3 mm; 2, history 
of congestive heart failure or left ventricular ejection fraction 
<30%; 1, prior PCI or prior MI; and 1, paclitaxel-eluting stent.12 
In the original analysis, higher DAPT score (≥2) predicted a 
larger reduction in ischemic risk and lesser increase in bleeding 
with continued therapy beyond 12 months relative to score <2.
A modified DAPT score was employed in the current analy-
sis, with 0 points allocated to paclitaxel-eluting stent and stent 
diameter <3 mm, as these data were not collected in REDUAL 
PCI. For cigarette smoking, 1 point was allocated for the cur-
rently smoker category but not the ex-smoker category, as 
information was not available on when patients stopped smok-
ing. Two modified DAPT score subgroups were included in this 
analysis: score <2 (Group A) and ≥2 (Group B).
Statistical Analysis
Cox proportional hazard regression models, stratified by age—
nonelderly versus elderly (age <70 years versus ≥70 years in 
Japan; <80 years versus ≥80 years elsewhere)—were used to 
compare dabigatran 110 mg dual therapy versus warfarin triple 
therapy, and unstratified Cox proportional hazard regression 
models to compare dabigatran 150 mg dual therapy versus 
warfarin triple therapy. Exploratory treatment by subgroup inter-
action P values were provided. An additional treatment-inde-
pendent stratified Cox proportional hazard regression analysis 
included complexity factor subgroup or modified DAPT score 
subgroup, respectively, as the only factor in the model.
RESULTS
Study Population
Most of the 2725 patients included in REDUAL PCI had 
either no procedural or clinical complexity factors (Group 
1: 37.0%) or clinical complexity factors alone (Group 
3: 43.1%; Table). Patients with procedural complexity 
factors had numerically higher rates of diabetes mel-
litus, stroke, and prior coronary artery disease with prior 
revascularization by PCI or coronary artery bypass graft 
than patients without complexity factors. CHA2DS2-VASc 
and modified HAS-BLED scores were similar between all 
groups. DAPT score at baseline was <2 in 67% of patients.
Effect of Complexity Factors on Treatment 
Outcomes
Bleeding Events
Complexity factor (clinical or procedural) had no effect 
on bleeding risk in the unadjusted, treatment-indepen-
dent analysis. Compared with patients without complex-
ity factors, hazard ratios (HRs) for bleeding risk were 
0.90 (95% CI, 0.66–1.21) for procedural complexity 
alone, 1.04 (95% CI, 0.86–1.25) for clinical complexity 
alone, and 1.03 (95% CI, 0.77–1.37) for both procedural 
and clinical complexity factors.
Risk of the primary bleeding end point was lower in 
both dabigatran dual therapy groups than warfarin triple 
therapy groups in all categories of clinical or procedural 
complexity (Figure 1). In the dabigatran 110 mg group, 
HRs were 0.56 (95% CI, 0.40–0.78) for no complexity 
factors, 0.58 (95% CI, 0.30–1.10) for procedural complex-
ity alone, 0.48 (95% CI, 0.35–0.65) for clinical complexity 
alone, and 0.47 (95% CI, 0.25–0.88) for both procedural 
and clinical complexity factors (interaction P value: 0.90). 
Respective HRs in the dabigatran 150 mg group were 
0.85 (95% CI, 0.60–1.20), 0.48 (0.22–1.02), 0.63 (0.46–
0.86), and 0.92 (0.48–1.77; interaction P value: 0.37).
Thromboembolic Events
In the unadjusted treatment-independent analysis, there 
was a trend to increased risk of DTE or unplanned revas-
cularization with greater complexity factor involvement. 
HRs for thromboembolic event or unplanned revascu-
larization were 1.13 (95% CI, 0.78–1.64) for procedural 
complexity alone, 1.29 (95% CI, 1.02–1.63) for clinical 
complexity alone, and 1.48 (95% CI, 1.05–2.08) for both 
procedural and clinical complexity factors compared with 
no complexity factors.
There was no significant interaction between com-
plexity factor subgroup and treatment on comparing 
dabigatran dual therapy and warfarin triple therapy with 
respect to thromboembolic events (interaction P values: 
0.67 and 0.54 for dabigatran 110 and 150 mg, respec-
tively; Figure 2). Efficacy seemed similar in both dabiga-
tran dual therapy groups compared with warfarin triple 
therapy groups, irrespective of procedural and/or clini-
cal complexity.
Numbers of stent thromboses were low in all groups, 
precluding interpretation of subgroup differences. Stent 
thrombosis rates were 1.2% (14/1174) for patients with 
clinical complexity alone, 0.4% (1/270) for procedural 
complexity alone, 1.8% (5/273) for both procedural and 
clinical complexity, and 1.0% (10/1008) for no com-
plexity factors.
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Effect of Modified DAPT Score on Treatment 
Outcomes
Bleeding Events
As expected, modified DAPT score ≥2 tended to be asso-
ciated with lower bleeding risk than score <2 (HR, 0.86 
[95% CI, 0.71–1.03]). Dabigatran dual therapy showed 
a benefit over warfarin triple therapy in bleeding risk 
events regardless of modified DAPT score. No interac-
tion between modified DAPT score subgroup and treat-
ment was observed (interaction P values: 0.53 and 0.54 
for dabigatran 110 and 150 mg, respectively; Figure 3).
Thromboembolic Events
In the unadjusted treatment-independent analysis, 
patients with modified DAPT score ≥2 were at higher risk 
of DTE or unplanned revascularization compared with 
patients with score <2 (HR, 1.59 [95% CI, 1.29–1.96]).
No interaction between modified DAPT score sub-
group and treatment was observed (interaction P val-
ues: 0.20 and 0.08 for dabigatran 110 and 150 mg, 
respectively; Figure 4). Similar efficacy was observed 
with dabigatran dual therapy versus warfarin triple ther-
apy, with some variations, that is, slightly higher risk of 
DTE or unplanned revascularization for both dabigatran 
dual therapy groups versus warfarin triple therapy in 
patients with modified DAPT score ≥2.
Stent thrombosis rates were low in both subgroups: 
1.0% (19/1816) for patients with modified DAPT score 
<2 and 1.2% (11/909) for those with score ≥2.
DISCUSSION
There has been a trend in recent years to replace triple 
therapy with dual therapy in patients with AF follow-
ing PCI, by eliminating the aspirin component.13–16 The 
WOEST study demonstrated that vitamin K antago-
nist and clopidogrel alone following PCI in patients on 
oral anticoagulation therapy reduced risk of bleeding 
without increasing the rate of thrombotic events ver-
sus triple therapy.17,18 Guidelines from the European 
Table. Baseline Characteristics According to Complexity Factor and Modified DAPT Score Subgroups
Characteristic
Complexity Factor Subgroups Modified DAPT Score Subgroups
Group 1 Group 2 Group 3 Group 4 Group A Group B
No Complexity 
Factors
Procedural  
Complexity  
Factors Only
Clinical  
Complexity Factors 
Only
Both Procedural 
and Complexity 
Factors DAPT <2 DAPT ≥2
n=1008 (37.0%) n=270 (10.0%) n=1174 (43.1%) n=273 (9.9%) n=1816 (66.6%) n=909 (33.4%)
Mean age, y (SD) 70.4 (8.1) 71.8 (8.0) 70.7 (9.2) 71.6 (8.8) 73.0 (7.7) 66.3 (8.8)
Age group
 Elderly 149 (14.8) 56 (20.7) 196 (16.7) 57 (20.9) 380 (20.9) 78 (8.6)
 Nonelderly 859 (85.2) 214 (79.3) 978 (83.3) 216 (79.1) 1436 (79.1) 831 (91.4)
Male sex 770 (76.4) 226 (83.7) 860 (73.3) 214 (78.4) 1341 (73.8) 729 (80.2)
Risk scores, mean (SD)
 CHA2DS2-VASc* 3.5 (1.5) 3.8 (1.5) 3.6 (1.6) 3.8 (1.6) 3.5 (1.5) 3.8 (1.6)
 Modified HAS-BLED† 2.7 (0.7) 2.8 (0.7) 2.7 (0.7) 2.7 (0.7) 2.8 (0.7) 2.5 (0.8)
Diabetes mellitus‡ 369 (36.6) 107 (39.6) 407 (34.7) 110 (40.3) 497 (27.4) 496 (54.6)
Renal insufficiency/failure§ 0 (0.0) 0 (0.0) 15 (1.3) 2 (0.7) 10 (0.6) 7 (0.8)
Previous stroke‡ 90 (8.9) 26 (9.6) 90 (7.7) 20 (7.3) 153 (8.4) 73 (8.0)
Previous PCI‡ 357 (35.4) 120 (44.4) 344 (29.3) 91 (33.3) 484 (26.7) 428 (47.1)
Previous stent thrombosis∥ 24 (2.4) 9 (3.3) 27 (2.3) 8 (2.9) 33 (1.8) 35 (3.9)
Previous CAD‡ 757 (75.1) 215 (79.6) 687 (58.5) 169 (61.9) 1126 (62.0) 702 (77.2)
Previous MI 215 (21.3) 68 (25.2) 321 (27.3) 95 (34.8) 330 (18.2) 369 (40.6)
Previous CABG‡ 89 (8.8) 49 (18.1) 106 (9.0) 43 (15.8) 158 (8.7) 129 (14.2)
Previous PE¶ 11 (1.1) 6 (2.2) 17 (1.4) 2 (0.7) 19 (1.0) 17 (1.9)
Previous SE‡ 5 (0.5) 2 (0.7) 10 (0.9) 4 (1.5) 12 (0.7) 9 (1.0)
Values are n (%) unless otherwise stated. AF indicates atrial fibrillation; CABG, coronary artery bypass graft; CAD, coronary artery disease; DAPT, dual antiplatelet 
therapy; MI, myocardial infarction; PCI, percutaneous coronary intervention; PE, pulmonary embolism; and SE, systemic embolism.
*CHA2DS2-VASc score reflects risk of stroke, with values ranging from 0 to 9 and higher scores indicating greater risk.
†HAS-BLED score reflects risk of major bleeding in patients with AF receiving anticoagulant therapy, with values ranging from 0 to 9 and higher scores indicating 
greater risk.
‡Data missing from 1 patient in Group 1 and 1 in Group A.
§Defined as baseline creatinine (CRE) value ≥2 mg/dL (using formula CRE/88.42).
∥Data missing from 16, 3, 21, and 4 patients in Groups 1, 2, 3, and 4, respectively; and 28 patients in Group A and 16 patients in Group B.
¶Data missing from 4, 1, and 3 patients in Groups 1, 2, and 3, respectively; and 5 patients in Group A and 3 patients in Group B.
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Society of Cardiology and CHEST recommend that 
triple therapy should be limited in duration in patients 
requiring anticoagulation post-PCI, based on individual 
patient risk of bleeding and ischemic events.3,19–21 The 
randomized trials of rivaroxaban (PIONEER AF-PCI) 
and dabigatran (REDUAL PCI) combined with single 
antiplatelet therapy support use of these novel oral 
anticoagulant dual therapies over vitamin K antago-
nist with triple therapy in patients with AF post-PCI,9,22 
consistent with North American and European Expert 
Consensus recommendations.6,23
This prespecified subgroup analysis of the REDUAL 
PCI trial found that dabigatran dual therapy following 
PCI was associated with consistently reduced bleeding 
risk compared with warfarin triple therapy, independent 
of the presence of procedural or clinical complexity fac-
tors. Dabigatran dual therapy at both doses had similar 
thrombotic risk to warfarin triple therapy, irrespective of 
complexity of PCI or modified DAPT score.
The DAPT trial reported that lesion complexity was a 
predictor of ischemic outcomes in patients who underwent 
PCI.8,24 Patients with complex lesions experienced signifi-
cantly increased rates of MI and stent thrombosis during 
12 months post-PCI compared with patients without com-
plex anatomy.8 On a shorter timescale, a substudy of the 
CHAMPION PHOENIX trial (Cangrelor Versus Standard 
Therapy to Achieve Optimal Management of Platelet Inhi-
bition PHOENIX) evaluating intravenous cangrelor versus 
a loading dose of clopidogrel in patients undergoing PCI 
reported that lesion complexity was predictive of early (<48 
hour) major adverse cardiovascular events.25 Longer-term 
analysis of patients treated with biodegradable polymer 
versus durable polymer stents in the BIOSCIENCE trial 
showed that clinical and lesion complexity were associated 
with higher rates of the composite end point of death, MI, 
or revascularization.26 Finally, anatomic complexity mea-
sured by a simplified scoring system (the Veterans Affairs 
SYNTAX score) successfully assessed longitudinal risk for 
adverse events in patients after PCI.27
The question was raised whether a dual antithrom-
botic strategy is sufficient in difficult-to-manage subpop-
ulations of patients with AF post-PCI. Our data suggest 
there may not be an increased risk of thrombotic com-
plications with dabigatran dual therapy compared with 
warfarin triple therapy, even in patients with clinical or 
procedural complexity. Of note, we have limited statistical 
power in any individual subgroup, but the overall benefit 
on bleeding and no major difference in thrombotic events 
seems consistent across the 4 patient groups with one 
or even both complexity factors. This provides reassur-
ance to clinicians on using this strategy as a means to 
reduce bleeding risk in patients needing both antiplatelet 
and anticoagulant therapy.
These findings parallel our analysis of patients with 
ACS versus non-ACS as the indication for PCI.28 Indeed, 
ACS is the main component of the prespecified clinical 
complexity definition. The current analysis, however, adds 
procedural complexity and assesses patients with both 
clinical and procedural complexities.
Although the analysis based on DAPT score was not 
prespecified, as the score was developed after the trial 
was started, the study provides support for the modified 
Figure 1. Bleeding events (International Society on Thrombosis and Haemostasis major bleeding event or clinically relevant 
nonmajor bleeding event) according to procedural and/or clinical complexity factor subgroups.
Hazard ratios (HRs) and 95% CIs from Cox proportional hazard model; stratified by age (elderly vs nonelderly) for dabigatran 110 mg dual 
therapy vs warfarin triple therapy; unstratified for dabigatran 150 mg dual therapy vs warfarin triple therapy. *For the comparison with dabigatran 
150 mg dual therapy, elderly patients outside the United States are excluded.
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DAPT score. The fact that patients with a DAPT score 
≥2 had higher risk of DTE or unplanned revascular-
ization than patients with score <2 in the unadjusted 
treatment-independent analysis is expected, given that 
higher DAPT scores are predictive of greater ischemic 
risk. For patients with DAPT score ≥2, a trend toward 
lower bleeding risk was observed, as would also be 
expected. The lack of a more considerable difference 
in bleeding risk between patients with DAPT scores ≥2 
or <2 might be explained by the different score distribu-
tion in this population, the effect of other contributing 
factors, or simply a lack of adequately powered analysis.
A limitation of this study is that it is a subgroup 
analysis and not powered for formal statistical analy-
sis. Interaction P values are exploratory. We also have 
insufficient power to examine individual end points 
across these 4 subgroups. A further limitation is the 
use of a modified DAPT score, which was required 
because 2 score components in the DAPT trial were 
not collected in REDUAL PCI; such a modification has 
not yet been validated.
In conclusion, these findings support the primary 
REDUAL PCI study and highlight the important finding 
that, even in higher-risk patients with clinical or lesion 
Figure 2. Thromboembolic events (death or thromboembolic event or unplanned revascularization) according to procedural 
and/or clinical complexity factor subgroups.
See Figure 1 for statistical summary. HR indicates hazard ratio.
Figure 3. Bleeding events (International Society on Thrombosis and Haemostasis major bleeding event or clinically relevant 
nonmajor bleeding event) according to modified dual antiplatelet therapy (DAPT) score (<2 versus ≥2).
For calculation of modified DAPT score see text. Missing values for calculation of DAPT score were imputed to 0 points. See Figure 1 for other 
statistical summary. HR indicates hazard ratio.
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complexity, bleeding risk can be mitigated without any 
apparent increase in ischemic risk by dabigatran dual 
therapy compared with warfarin triple therapy.
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